Acute respiratory distress syndrome following alemtuzumab therapy for relapsing multiple sclerosis.
Sign Up to like & getrecommendations! Published in 2017 at "Multiple sclerosis and related disorders"
DOI: 10.1016/j.msard.2017.03.001
Abstract: We present the case of a 54 year old woman with known relapsing-remitting multiple sclerosis who presented with acute respiratory deterioration five weeks after a first course of alemtuzumab. Imaging showed bilateral ground glass changes… read more here.
Keywords: following alemtuzumab; acute respiratory; multiple sclerosis; alemtuzumab therapy ... See more keywords
Highly active RRMS and ocrelizumab after failure of alemtuzumab therapy
Sign Up to like & getrecommendations! Published in 2020 at "BMC Neurology"
DOI: 10.1186/s12883-020-01789-y
Abstract: Background A high multiple sclerosis activity while on alemtuzumab is rather uncommon compared to moderate-efficacy drugs. The purpose of this case report is to present a case of a 37-year-old female patient with bronchial asthma… read more here.
Keywords: active rrms; rrms ocrelizumab; highly active; alemtuzumab therapy ... See more keywords
Failure of alemtuzumab therapy to control MOG encephalomyelitis
Sign Up to like & getrecommendations! Published in 2017 at "Neurology"
DOI: 10.1212/wnl.0000000000004087
Abstract: Myelin oligodendrocyte glycoprotein (MOG) immunoglobulin G (IgG)–associated encephalomyelitis (EM) is a rare autoimmune disorder that displays substantial clinicoradiologic overlap with aquaporin-4 (AQP4)-IgG-seropositive neuromyelitis optica spectrum disorders (NMOSD) and classic multiple sclerosis (MS).1–3,e1 The long-term outcome… read more here.
Keywords: igg; failure alemtuzumab; encephalomyelitis; therapy control ... See more keywords